Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
13/05/2026 13:08
May 13 (Reuters) - Urogen Pharma Ltd UR8.F: UROGEN PHARMA LTD - REPORTS 36-MONTH DURATION OF RESPONSE OF 64.5% FOR ZUSDURI IN PHASE 3 ENVISION TRIAL UROGEN PHARMA LTD - MEDIAN DURATION OF RESPONSE NOT REACHED AT 35.5 MONTHS FOLLOW-UP UROGEN PHARMA LTD - SERIOUS ADVERSE REACTIONS OCCURRED IN 12% OF PATIENTS IN ENVISION TRIAL Source text: ID:nGNX5Rj2py Further company coverage: UR8.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors